이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Co-Diagnostics 관리

관리 기준 확인 2/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Dwight Egan

최고 경영자

US$1.3m

총 보상

CEO 급여 비율	29.7%
CEO 임기	11.4yrs
CEO 소유권	1.2%
경영진 평균 재임 기간	less than a year
이사회 평균 재임 기간	3.8yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Dwight Egan 의 보수는 Co-Diagnostics 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Jun 30 2024	n/a	n/a	-US$38m
Mar 31 2024	n/a	n/a	-US$39m
Dec 31 2023	US$1m	US$375k	-US$35m
Sep 30 2023	n/a	n/a	-US$43m
Jun 30 2023	n/a	n/a	-US$38m
Mar 31 2023	n/a	n/a	-US$32m
Dec 31 2022	US$2m	US$366k	-US$14m
Sep 30 2022	n/a	n/a	US$15m
Jun 30 2022	n/a	n/a	US$28m
Mar 31 2022	n/a	n/a	US$40m
Dec 31 2021	US$2m	US$350k	US$37m
Sep 30 2021	n/a	n/a	US$42m
Jun 30 2021	n/a	n/a	US$46m
Mar 31 2021	n/a	n/a	US$51m
Dec 31 2020	US$1m	US$309k	US$42m
Sep 30 2020	n/a	n/a	US$28m
Jun 30 2020	n/a	n/a	US$10m
Mar 31 2020	n/a	n/a	-US$6m
Dec 31 2019	US$460k	US$275k	-US$6m
Sep 30 2019	n/a	n/a	-US$6m
Jun 30 2019	n/a	n/a	-US$6m
Mar 31 2019	n/a	n/a	-US$6m
Dec 31 2018	US$474k	US$275k	-US$6m
Sep 30 2018	n/a	n/a	-US$6m
Jun 30 2018	n/a	n/a	-US$8m
Mar 31 2018	n/a	n/a	-US$8m
Dec 31 2017	US$210k	US$195k	-US$7m

보상 대 시장: Dwight 의 총 보상 ($USD 1.26M )은 German 시장( $USD 434.78K ).

보상과 수익: Dwight 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Dwight Egan (71 yo)

11.4yrs

테뉴어

US$1,261,300

보상

Mr. Dwight H. Egan serves as the Chairman & Chief Executive Officer and was President at Co-Diagnostics, Inc. and has been its Director since April 2013. Mr. Egan has been engaged in private investment bus...

리더십 팀

이름	위치	테뉴어	보상	소유권
Dwight Egan	Chairman & CEO	no data	US$1.26m	1.15% $ 404.5k
Brian Brown	CFO & Company Secretary	3.6yrs	US$1.04m	0.91% $ 320.2k
Richard Abbott	President	less than a year	데이터 없음	1.85% $ 650.8k
Brent Satterfield	Co-Founder & Member of Scientific Advisory Board	11.4yrs	US$237.50k	데이터 없음
David Nielsen	Chief Operating Officer	less than a year	데이터 없음	데이터 없음
Dan Bohrer	Vice President of Finance & Accounting	no data	데이터 없음	데이터 없음
Christopher Thurston	Chief Technology Officer	less than a year	데이터 없음	데이터 없음
Andrew Benson	Head of Investor Relations	no data	데이터 없음	데이터 없음
Mayuranki Almaula	Senior Vice President of Overseas Operations & Strategic Alliances	no data	데이터 없음	데이터 없음
Cameron Gundry	Head of Commercialization LATAM/EUR	no data	데이터 없음	데이터 없음
Ivory Chang	Chief Regulatory Affairs Officer	1.1yrs	데이터 없음	데이터 없음
Seth Egan	Chief Commercialization Officer	less than a year	데이터 없음	데이터 없음

0.5yrs

평균 재임 기간

50yo

평균 연령

경험이 풍부한 관리: C97 의 관리팀은 경험 (평균 재직 기간 0.3 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Dwight Egan	Chairman & CEO	11.4yrs	US$1.26m	1.15% $ 404.5k
Brent Satterfield	Co-Founder & Member of Scientific Advisory Board	2.5yrs	US$237.50k	데이터 없음
Richard Serbin	Independent Director	7.3yrs	US$298.00k	0.37% $ 129.4k
Carl Wittwer	Chairman of Scientific Advisory Board	2.5yrs	데이터 없음	데이터 없음
James Nelson	Independent Director	5.1yrs	US$298.00k	0.36% $ 126.7k
Noriko Kusukawa	Member of Scientific Advisory Board	2.5yrs	데이터 없음	데이터 없음
Edward Murphy	Independent Director	5.3yrs	US$298.00k	0.40% $ 140.5k
Eugene Durenard	Independent Director	5.3yrs	US$298.00k	0.36% $ 126.7k
Karen Carroll	Member of Scientific Advisory Board	2.5yrs	데이터 없음	데이터 없음
Anne Wyllie	Member of Scientific Advisory Board	2.5yrs	데이터 없음	데이터 없음

3.8yrs

평균 재임 기간

59yo

평균 연령

경험이 풍부한 이사회: C97 의 이사회는 경험(평균 재직 기간 3.5 년)으로 간주됩니다.

Co-Diagnostics 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Co-Diagnostics, Inc., Annual General Meeting, Aug 29, 2024

Co-Diagnostics, Inc. Appoints Executive Appointments

Co-Diagnostics, Inc. Appoints Ivory Chang as Chief Regulatory Affairs Officer

Co-Diagnostics, Inc., Annual General Meeting, Aug 30, 2023

High number of new and inexperienced directors

Co-Diagnostics, Inc. Appoints Dr. Mark Poritz as New Chief Scientific Officer

Recent updates

Second quarter 2024 earnings released: US$0.25 loss per share (vs US$0.31 loss in 2Q 2023)

Co-Diagnostics, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Co-Diagnostics, Inc., Annual General Meeting, Aug 29, 2024

Co-Diagnostics, Inc. Submits First FDA 510(k) Application for Co-Dx PCR Pro Platform

First quarter 2024 earnings released: US$0.31 loss per share (vs US$0.20 loss in 1Q 2023)

New minor risk - Shareholder dilution

Co-Diagnostics, Inc. to Report Q1, 2024 Results on May 09, 2024

Co-Diagnostics, Inc. Appoints Executive Appointments

Full year 2023 earnings released: US$1.20 loss per share (vs US$0.45 loss in FY 2022)

Co-Diagnostics, Inc. to Report Q4, 2023 Results on Mar 14, 2024

Co-Diagnostics, Inc. Completes Submission to FDA for Co-Dx PCR Pro

Third quarter 2023 earnings released: US$0.20 loss per share (vs US$0.043 loss in 3Q 2022)

Co-Diagnostics, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Co-Diagnostics, Inc. Appoints Ivory Chang as Chief Regulatory Affairs Officer

Second quarter 2023 earnings released: US$0.31 loss per share (vs US$0.083 loss in 2Q 2022)

Co-Diagnostics, Inc. to Report Q2, 2023 Results on Aug 10, 2023

New major risk - Share price stability

Co-Diagnostics, Inc., Annual General Meeting, Aug 30, 2023

Co-Diagnostics, Inc. Receives Funding for Co-Dx PCR Home Platform from NIH RADx Tech Program

First quarter 2023 earnings released: US$0.20 loss per share (vs US$0.34 profit in 1Q 2022)

Co-Diagnostics, Inc. to Report Q1, 2023 Results on May 11, 2023

Full year 2022 earnings released: US$0.45 loss per share (vs US$1.27 profit in FY 2021)

Third quarter 2022 earnings released: US$0.043 loss per share (vs US$0.40 profit in 3Q 2021)

High number of new and inexperienced directors

Third quarter 2022 earnings released: US$0.043 loss per share (vs US$0.40 profit in 3Q 2021)

Co-Diagnostics, Inc. Appoints Dr. Mark Poritz as New Chief Scientific Officer

Co-Diagnostics, Inc. to Report Q3, 2022 Results on Nov 10, 2022

Pomerantz Law Firm Announces the Filing of a Class Action Against Co-Diagnostics, Inc. and Certain Officers

Investor sentiment deteriorated over the past week

Kaplan Fox & Kilsheimer LLP Files Class Action Suit in the United States District Court for the Southern District of New York Against Co-Diagnostics, Inc

Second quarter 2022 earnings released: US$0.083 loss per share (vs US$0.34 profit in 2Q 2021)

Co-Diagnostics, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Co-Diagnostics, Inc., Annual General Meeting, Aug 31, 2022

Now 23% undervalued after recent price drop

Investor sentiment improved over the past week

Now 21% undervalued after recent price drop

Co-Diagnostics, Inc. Completes Principal Design of Test for Monkeypox Virus

Investor sentiment improved over the past week

First quarter 2022 earnings released: EPS: US$0.34 (vs US$0.28 in 1Q 2021)

High number of new and inexperienced directors

Investor sentiment deteriorated over the past week

High number of new and inexperienced directors

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Co-Diagnostics, Inc. (NasdaqCM:CODX) completed the acquisition of Advanced Conceptions, Inc.

Co-Diagnostics, Inc. (NasdaqCM:CODX) entered into an Agreement and Plan of Merger to acquire Idaho Molecular Inc.

Third quarter 2021 earnings released: EPS US$0.40 (vs US$0.56 in 3Q 2020)

Co-Diagnostics, Inc. to Introduce at Home/Point of Care Device at AACC on Sept 28

Co-Diagnostics, Inc. SARS-CoV-2 Test Used in New Community Surveillance Method in Italy

Investor sentiment improved over the past week

Second quarter 2021 earnings released: EPS US$0.34 (vs US$0.54 in 2Q 2020)

Co-Diagnostics, Inc. Provides Earnings Guidance for the Third Quarter 2021

Investor sentiment improved over the past week

Co-Diagnostics, Inc.(NasdaqCM:CODX) dropped from Russell 3000E Index

Co-Diagnostics, Inc Receives CE Marking for Direct Saliva SARS-CoV-2 Test

Investor sentiment improved over the past week

First quarter 2021 earnings released: EPS US$0.28 (vs US$0.047 loss in 1Q 2020)

Co-Diagnostics, Inc. Provides Earnings Guidance for the Second Quarter of Fiscal 2021

Investor sentiment deteriorated over the past week

Full year 2020 earnings released: EPS US$1.59 (vs US$0.37 loss in FY 2019)

Co-Diagnostics Provides Earnings Guidance for the First Quarter of 2021

Co-Diagnostics, Inc. to Report Q4, 2020 Results on Mar 25, 2021

Co-Diagnostics, Inc. Announces the Development of A New Point-Of-Care/At Home PCR Diagnostic Testing, Screening and Surveillance Platform

Co-Diagnostics, Inc. Partner to Offer At-Home Saliva Collection Kits for CoPrimer™-Based Covid-19 PCR Test Through Walgreens Find Care®

Investor sentiment deteriorated over the past week

Co-Diagnostics, Inc. Announces CFO Chnages

New 90-day high: €16.20

Investor sentiment improved over the past week

Co-Diagnostics, Inc. Completes FDA EUA Submission for Extraction-Free Saliva COVID-19 Test